Page last updated: 2024-11-04

3,6-diamino-10-methylacridinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,6-diamino-10-methylacridinium : The cation obtained from 3,6-diaminoacridine by methylation of the nitrogen at position 10. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2016
CHEMBL ID1184529
CHEBI ID60585
SCHEMBL ID278580
MeSH IDM0087253

Synonyms (48)

Synonym
5-22-11-00323 (beilstein handbook reference)
3,6-diamino-10-methylacridine
acridinium, 3,6-diamino-10-methyl-
3,6-diamino-10-methylacridinium
brn 3553796
KBIO1_000244
DIVK1C_000244
SPECTRUM_000752
IDI1_000244
SPECTRUM5_001306
NCGC00178831-01
panflavin
flavine
nsc2755
xanthacridine
acriflavon
10-methylacridin-10-ium-3,6-diamine
BSPBIO_002076
KBIO2_003800
KBIO2_006368
KBIOGR_000909
KBIO2_001232
KBIOSS_001232
KBIO3_001576
SPECTRUM2_000066
SPECTRUM4_000385
NINDS_000244
SPBIO_000251
SPECTRUM3_000598
10-methylacridin-10-ium-3,6-diamine chloride
xsioktwdeojmgg-uhfffaoysa-
inchi=1/c14h13n3/c1-17-13-7-11(15)4-2-9(13)6-10-3-5-12(16)8-14(10)17/h2-8h,1h3,(h3,15,16)/p+1
837-73-0
CHEBI:60585 ,
CHEMBL1184529
SCHEMBL278580
DTXSID30232534
bdbm114204
(6-amino-10-methyl-acridin-10-ium-3-yl)amine;chloride;hydrochloride
cid_15558347
10-methyl-3,6-diaminoacridinium chloride
bdbm200233
cid_2016
ab00053810_11 ,
SBI-0051559.P002
Q27128060
3,6-diamino-10-methylacridin-10-ium
acriflavinium
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acridinium ion
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cystic fibrosis transmembrane conductance regulatorHomo sapiens (human)IC50 (µMol)5.71000.140016.625050.0000AID1224863
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NPYLR7BAedes aegypti (yellow fever mosquito)EC50 (µMol)0.03900.03902.289918.3000AID1259426
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (94.44)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.33 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]